Phosphodiesterase type 5 inhibitors: back and forward from cardiac indicationsReportar como inadecuado

Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Journal of Endocrinological Investigation

, Volume 39, Issue 2, pp 143–151

First Online: 28 June 2015Received: 19 March 2015Accepted: 11 June 2015DOI: 10.1007-s40618-015-0340-5

Cite this article as: Corinaldesi, C., Di Luigi, L., Lenzi, A. et al. J Endocrinol Invest 2016 39: 143. doi:10.1007-s40618-015-0340-5


PDE5 inhibitors PDE5i are widely known as treatment for erectile dysfunction ED. This favorable action has emerged as a -side effect- from pioneering studies when PDE5i have been originally proposed as treatment for coronary artery disease CAD. PDE5i showed marginal benefits for CAD treatment; although disappointing for that indication, they improved systemic and pulmonary vasodilation and ameliorated general endothelial function. Therefore, PDE5i have been approved and licensed also for pulmonary artery hypertension PAH, besides ED. Nowadays, fine-tuned biomolecular mechanisms of PDE5i are well recognized to be beneficial onto myocardial contractility and geometry, to reduce tissue fibrosis, hypertrophy and apoptosis. PDE5i consistently exert benefits on heart failure, infarct, cardiomyopathy. The concept that PDE5i likely blunt Th1-driven inflammatory processes, which shift the homeostatic balance from health to disease, has emerged; PDE5i seem to decrease the release of active biomolecules from cells to tissues interested by inflammation. In this view, following clinical and basic research progresses, PDE5i can be undoubtedly -re-allocated- for cardiac indications and, hopefully, they could be approved as therapeutic tools to treat and prevent heart disease. This review aims to summarize PDE5i different clinical applications, from past to present and future, focusing on their potential power as treatment for cardiac diseases.

KeywordsPDE5 inhibitors Cardioprotection Inflammation  Download fulltext PDF

Autor: C. Corinaldesi - L. Di Luigi - A. Lenzi - C. Crescioli


Documentos relacionados